152 related articles for article (PubMed ID: 31989369)
21. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.
Coart E; Barrado LG; Duits FH; Scheltens P; van der Flier WM; Teunissen CE; van der Vies SM; Burzykowski T;
J Alzheimers Dis; 2015; 46(4):889-99. PubMed ID: 25869788
[TBL] [Abstract][Full Text] [Related]
22. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings.
Sabbagh MN; Shi J; Lee M; Arnold L; Al-Hasan Y; Heim J; McGeer P
BMC Neurol; 2018 Sep; 18(1):155. PubMed ID: 30257642
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
24. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls.
Struyfs H; Molinuevo JL; Martin JJ; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2014; 41(3):903-9. PubMed ID: 24705548
[TBL] [Abstract][Full Text] [Related]
25. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
[TBL] [Abstract][Full Text] [Related]
26. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
27. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
28. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
29. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias.
De Riva V; Galloni E; Lealini B; Zarantonello G; Disco C; Dionisio LD; Meligrana L; Marcon M; Perini F
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115229
[TBL] [Abstract][Full Text] [Related]
30. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
33. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
[TBL] [Abstract][Full Text] [Related]
34. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.
Reale M; Gonzales-Portillo I; Borlongan CV
Brain Res; 2020 Jan; 1727():146535. PubMed ID: 31669827
[TBL] [Abstract][Full Text] [Related]
35. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
36. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.
Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S
J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986
[TBL] [Abstract][Full Text] [Related]
37. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
38. A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers.
Spies PE; Claassen JA; Peer PG; Blankenstein MA; Teunissen CE; Scheltens P; van der Flier WM; Olde Rikkert MG; Verbeek MM
Alzheimers Dement; 2013 May; 9(3):262-8. PubMed ID: 23123231
[TBL] [Abstract][Full Text] [Related]
39. No association of salivary total tau concentration with Alzheimer's disease.
Ashton NJ; Ide M; Schöll M; Blennow K; Lovestone S; Hye A; Zetterberg H
Neurobiol Aging; 2018 Oct; 70():125-127. PubMed ID: 30007161
[TBL] [Abstract][Full Text] [Related]
40. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
